



IFW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

ELDAR-FINKELMAN Hagit

Serial No.: 10/810,578

Filed: March 29, 2004

For: GLYCOGEN SYNTHASE KINASE-3 INHIBITORS

Examiner:

§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1645

Attorney
Docket: 27457

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This application is a Divisional of 09/951,902 filed 09/14/2001 which is a CIP of PCT/US01/00123 filed 01/03/2001. Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,


Sol Sheinbein
Registration No. 25,457

Dated: March 31, 2005

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, this collection of information is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/810,578
				Filing Date	September 14, 2001
				First Named Inventor	ELDAR-FINKELMAN
				Group Art Unit	1645
Examiner Name					
Sheet	2	Of	2	Attorney Docket Number	27457
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	9	Eldar-Finkleman et al. "The Insulin Mimetic Action of Glycogen Synthase Kinase-3 Inhibitors", Diabetologia, 45(Suppl.2): A 70, 38 th Annual Meeting for the European Association for the Study of Diabetes (EASD), Budapest, Hungary, 2002. Abstract.			
	10	Plotkin et al. "Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3", Journal of Pharmacology and Experimental Therapeutics, 305(3): 974-980, 2003.			
	11	Leclerc et al. "Indirubins Inhibit Glycogen Synthase Kinase-3 β and CDK5/P25, Two Proteins Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease", The Journal of Biological Chemistry, 276(1): 251-260, 2001.			
	12	Hotamisligil et al. "IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNT- α - and Obesity-Induced Insulin Resistance", Science, 271: 665-, 1996.			
	13	Tanti et al. "Serine/Threonine Phosphorylation of Insulin Receptor Substrate 1 Modulates Insulin Receptor Signaling", The Journal of Biological Chemistry, 269(8): 6051-6057, 1994.			
	14	Fahraeus et al. "Inhibition of PRB Phosphorylation and Cell-Cycle Progression by a 20-Residue Peptide Derived from P16 CDKN2/INK4A", Current Biology, 6(1): 84-91, 1996.			
	15	Mitchell et al. "Heat-Stable Inhibitor Protein Derived Peptide Substrate Analogs: Phosphorylation by γ -Dependent and cGMP-Dependent Protein Kinases", Am. Chemical Soc., 1994.			
	16	Maniatis "Signal Transduction: Catalysis by a Multiprotein I κ B Kinase Complex", Science, 278(5339): 818, 1997. Extract.			
	27	American Diabetes Association "Standards of Medical Care for Patients With Diabetes Mellitus", Diabetes Care, 17(6): 616-623, 1994.			
	28	Hawiger, J., "Non-Invasive Intracellular Delivery of Functional Peptides", Curr. Opin. Chem. Biol., 3:89-94, 1999			
Signature				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.